|
| Winstrol dosage: |
Alot of what holds true for the injectable version of this product (see: Winstrol Depot) also holds for the tabs. There are, however, two noticable differences between the two forms of administration. Nitrogen Retention is greater with use of the injectable version, when equal doses are administered. Paradoxically, it would seem that on a milligram for milligram basis, users have reported that oral administration of Stanozolol was more potent than the injectable produc for building muscle. This could be due to winstrol's ability to lower SHBG (Sex Hormone Binding Globulin) levels and also elevate IGF (Insulin-Like Growth Factor) above those experienced with the injectable version.
British Dragon winstrol tabs are one of the most popular versions on the market today. Women athletes commonly reported the use of Stanozolol at a dosage of 10mg daily, and I am of the opinion that women should preferentially use the injectable version when possible.
Men have found that it works well when used in 50-100mg daily doses, and stacked very efficiently with Testosterone and Nandrolone or Trenbolone.
Reported Characteristics:
Pharmaceutical Name:Stanozolol Chemical Name:17-beta-hydroxy-17-methyl-5alpha-androstano[3,2-c]pyrazole Cutting/Bulking:Cutting Anabolic Rating:320 Active-Life: About 8 hours Drug Class: Anabolic/Androgenic steroid (Oral) Average Reported Dosage: Males 25-50-mg daily Women 10mg daily Acne: Possible Water Retention: No High Blood Pressure: Rare Liver Toxic: High in high oral dosages DHT Conversion: DHT-derived Decreases HPTA Function: No Average Price:Up to $1/10mg tab
|
| |
| Research Findings Expected to Ease Treatment of Low Neutrophil Counts in Cancer PatientsMulticenter trial led by St. Jude Children's Research
Hospital investigators may change neutropenia treatment for all
childhood cancer patients
MEMPHIS, Tenn., March 10 /PRNewswire-USNewswire/ -- For patients
like 10-year-old Sabrina Jo Spence, new...



QLT Announces Phase II Clinical Trial Results and Development Plans for the Punctal Plug Delivery System-- 90-Day Retention Rate of 81% for Latest Punctal Plug
Prototype Device -- No Dose Response Seen with Higher Doses in
Phase II Clinical Studies -- Expand Development Plans of the
Punctal Plug Delivery System in Allergic Conjunctivitis --...



AM-Pharma presents positive results for Phase II trial in Acute Kidney InjuryAM-Pharma presents positive Phase II results for potential
First-In-Class drug
AM-Pharma presents positive results of its Phase II clinical
trial with Alkaline Phosphatase in Acute Kidney Injury at the
ISICEM conference in Brussels Alkaline...



Medicine to Lower Blood Pressure Significantly Decreases Risk For Cardiovascular Disease, StrokeStudy highlights:
Medicine to lower blood pressure decreased risk of
cardiovascular disease, including stroke, by more than 25 percent
among normal weight, overweight and obese patients.
Obese patients, who had higher initial blood pressure...



Acologix Presents Data on Cartilage Regeneration by AC-100 at the 56th Annual Meeting of the Orthopaedic Research SocietyHAYWARD, Calif., March 6 /PRNewswire/ -- Acologix, Inc., a
privately held biopharmaceutical company, today announced the
results of its latest preclinical study demonstrating that AC-100,
its therapeutic product candidate derived from an endogenous...



Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase InhibitorsREDWOOD CITY, Calif., March 8 /PRNewswire-FirstCall/ -- Genomic
Health, Inc. (NASDAQ:GHDX) today announced the publication of
positive results from a large international study which
demonstrated that the Oncotype DX® breast cancer...



New Data Presented at American Burn Association's Annual Meeting Support Safety Profile of RECOTHROM Thrombin, Topical (Recombinant) in Pediatric PatientsSEATTLE--(BUSINESS WIRE)--Mar 9, 2010 - ZymoGenetics, Inc.
(NASDAQ:ZGEN), today announced the presentation of safety and
immunogenicity data among pediatric burn patients at the
42nd Annual Meeting of the American Burn Association in
Boston, MA. The...



Mayo Researchers Link Obesity to Worse Outcome in Patients Being Treated for Colon CancerResearchers say that obesity leads to more aggressive colon
cancer and that the risk differs between men and women
ROCHESTER, Minn.--(BUSINESS WIRE)--Mar 9, 2010 - It's long been
known that obesity is linked to increased risk of developing...



BioMimetic Therapeutics Presents Promising Pre-Clinical Sports Medicine Data at the 2010 ORS MeetingData Demonstrates rhPDGF-BB, in Combination with Tissue
Specific Matrix Materials, Promotes Healing in Achilles and Rotator
Cuff Tears
FRANKLIN, Tenn.--(BUSINESS WIRE)--Mar 9, 2010 - BioMimetic
Therapeutics, Inc. (NASDAQ: BMTI) announced...



Inhibitex to Present at Two Upcoming ConferencesATLANTA--(BUSINESS WIRE)--Mar 8, 2010 - Inhibitex, Inc. (Nasdaq:
INHX), today announced that Russell H. Plumb, President and Chief
Executive Officer, is scheduled to present an overview of the
company and its pipeline of differentiated antiviral...



Warfarin Users Appear More Likely To Develop Brain Bleeding Following Stroke TreatmentCHICAGO, March 8, 2010-Patients already taking warfarin who
develop an acute stroke appear more likely to experience a brain
hemorrhage following treatment with an intravenous clot-dissolving
medication, even if their blood clotting function...



INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray- Unique delivery method achieves statistical significance in
five minutes
PHOENIX, March 09, 2010 /PRNewswire/ -- INSYS Therapeutics, Inc.
announces positive results from the pivotal phase III efficacy
trial for patients...



Nektar Announces Positive Prelim. Data for NKTR-102 in Ovarian CancerSAN CARLOS, Calif., March 8, 2010 -- Nektar Therapeutics
(Nasdaq: NKTR) today announced preliminary progression-free
survival data from the first stage of a two-stage Phase 2 clinical
study evaluating single-agent treatment with NKTR-102 in women...



Omthera Pharmaceuticals, Inc. Closes a $6.5M Series A led by Sofinnova Partners to Advance Epanova, a Prescription Omega 3 TherapyDyslipidemia Experts Jerry Wisler and Michael Davidson, M.D.
Co-Found New Pharmaceutical Company Developing a Prescription Omega
3 Treatment of High Triglycerides
NEW YORK--(BUSINESS WIRE)--Mar 8, 2010 - Omthera
Pharmaceuticals, Inc., an...



Nektar Announces Positive Phase 2 Clinical Data from First Stage of NKTR-102 Study in Women with Platinum-Resistant Ovarian CancerSAN CARLOS, Calif., March 8 /PRNewswire-FirstCall/ -- Nektar
Therapeutics (NASDAQ:NKTR) today announced preliminary
progression-free survival data from the first stage of a two-stage
Phase 2 clinical study evaluating single-agent treatment...



Millennium Announces First Clinical Data For TAK-700 Prostate Molecule at ASCO GUCAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 8, 2010 -
Millennium: The Takeda Oncology Company today announced the
presentation of safety, pharmacokinetic and efficacy data from the
Phase I portion of a Phase I/II clinical trial evaluating TAK-700
in...



Argos Therapeutics Presents Positive Phase 2 Data of its Arcelis Personalized Immunotherapy Platform in Metastatic RCC at ASCO GU Symposium-Immunotherapy Demonstrates Encouraging Immune and Clinical
Responses-
DURHAM, N.C.--(BUSINESS WIRE)--Mar 8, 2010 - Argos Therapeutics
today announced the presentation of positive data from a Phase 2
trial that evaluated the safety,...



New Imiquimod Formulation for Actinic Keratosis published in JAADStudy Examining New Short-Course Imiquimod Formulation in
Actinic Keratosis published in Journal of the American Academy of
Dermatology
Imiquimod 3.75% Is Now Available In Pharmacies Across Canada
TORONTO, ON, March 8, 2010 – The Journal of...



Recentin Did Not Meet Primary Endpoint in Horizon III Study in Metastatic Colorectal CancerLONDON, March 8, 2010--
AstraZeneca today announced the top-line
results of a Phase II/III study evaluating RECENTIN
(cediranib) compared with Avastin (bevacizumab) in
patients with first-line metastatic colorectal cancer (mCRC).
This study,...



Genmab Announces Results from Zalutumumab Phase III Study of Refractory Head and Neck Cancer PatientsCopenhagen, Denmark; March 08, 2010 – Genmab
A/S (OMX: GEN) announced today top-line results from
a zalutumumab Phase III study in patients
with recurrent or metastatic squamous cell carcinoma of the head
and neck (SCCHN) who failed standard...



Scientists Find New Form of Prion Disease that Damages Brain ArteriesStudy in Mice May Offer Clues for Treating Alzheimer's
Disease
WHAT: National Institutes of Health (NIH) scientists
investigating how prion diseases destroy the brain have observed a
new form of the disease in mice that does not cause the...



Poniard Pharmaceuticals Presents Positive Survival Data from a Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer at the 2010 American Society of Clinical Oncology Genitourinary Cancers SymposiumSOUTH SAN FRANCISCO, Calif., March 5 /PRNewswire-FirstCall/ --
Poniard Pharmaceuticals, Inc. (NASDAQ:PARD) , a biopharmaceutical company
focused on innovative oncology therapies, today announced the
presentation of positive final data, including...



Poniard Pharm Presents Positive Survival Data from a P2 Study in Metastatic Prostate CancerPoniard Pharmaceuticals Presents Positive Survival Data from a
Phase 2 Clinical Study of Picoplatin in Metastatic Prostate Cancer
at the 2010 American Society of Clinical Oncology Genitourinary
Cancers Symposium
SOUTH SAN FRANCISCO, Calif. –...



Common Osteoporosis Drugs Are Associated With a Decrease in Risk of Breast CancerSEATTLE, March 5 /PRNewswire/ -- Women who take some types of
bone-building drugs used to prevent and treat osteoporosis may be
at lower risk of breast cancer, according to a study by U.S.
researchers published today in the British Journal of...



Researchers Report that Thymosin beta 4 Improves Neurological Function after StrokeTβ4 Found to Stimulate Oligoprogenitor
Cells
ROCKVILLE, Md.--(BUSINESS WIRE)--Mar 5, 2010 - REGENERX
BIOPHARMACEUTICALS, INC. (NYSE Alternext US:RGN) announced that
a research team from the Henry Ford Hospital in Detroit, MI
reported that...



Experimental Vaccine Protects Monkeys Against ChikungunyaMosquito-borne virus has infected millions of people in Asia,
Africa and Europe
GALVESTON, Texas — Imagine a mosquito-borne virus that has
already infected millions of people in recent outbreaks in South
and Southeast Asia, the islands of the...



Open-Label Study Supports Long-Term Efficacy Of Xenazine (Tetrabenazine) For HD ChoreaResults achieved over 80 weeks of treatment consistent with
statistically significant reduction in chorea associated with
Huntington's disease demonstrated in pivotal study
DEERFIELD, Ill., March 5, 2010 – Lundbeck Inc. today
announced the...



Phase III REGION-I Study Shows PEP005 (ingenol mebutate) Gel 0.05% May Reduce Pre-Cancerous Skin Lesions in Patients with Actinic KeratosisData Presented at the 68th Annual Meeting of the American
Academy of Dermatology
PARSIPPANY, N.J., March 5 /PRNewswire/ -- Specialty
pharmaceutical company LEO Pharma today announced that findings
from a Phase III study evaluating PEP005...



ADVANCE-2 Study Results Demonstrate Investigational Anticoagulant Apixaban Was Statistically Superior To Enoxaparin In The Prevention Of Venous Thromboembolism Following Knee Replacement SurgeryPhase III Data Published in The Lancet also Demonstrate
Comparable Rates of Bleeding with Apixaban Versus
Enoxaparin
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Mar 4, 2010 -
Apixaban, an oral anticoagulant being developed by
Bristol-Myers...



Presentations on Geron's Telomerase Inhibitor At AACR Special ConferenceData Shows Activity of Imetelstat Against Cancer Stem
Cells
MENLO PARK, Calif.--(BUSINESS WIRE)--Mar 2, 2010 - Geron
Corporation (Nasdaq:GERN) today announced several presentations at
the American Association for Cancer Research (AACR)...



Beta Blocker Therapy Underused in Heart Failure PatientsNew Saint Louis U research suggests reliance on technology
rather than drug therapy
ST. LOUIS, March 4, 2010 – New Saint Louis University
research has found that beta blockers, a class of drugs used to
prevent the progression of heart failure...



Argos Therapeutics Publishes Positive Immune Response, Safety and Manufacturing Data for its Arcelis? HIV Program in Clinical ImmunologyDURHAM, N.C.--(BUSINESS WIRE)--Mar 4, 2010 - Argos Therapeutics
today announced the publication of a manuscript in the February
edition of Clinical Immunology, detailing positive immune
response, safety and manufacturing data for its...



Negative Phase III Trial Results for Latrepirdine (Dimebon)Alzheimer's Association Statement
CHICAGO, March 3 /PRNewswire-USNewswire/ -- "The Alzheimer's
Association is disappointed to learn of the negative results from
the Phase III clinical trial of latrepirdine (Dimebon)," said
William Thies, Ph.D.,...



Stelara and Remicade Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) MeetingMIAMI, March 4 /PRNewswire/ -- Data evaluating the efficacy and
safety of STELARA(TM) (ustekinumab) and REMICADE® (infliximab)
in patients with plaque psoriasis who had an inadequate response to
Enbrel® (etanercept) will be presented at the...



Dendreon Presents Updated IMPACT Results Confirming Provenge Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer-- Data to be Presented at ASCO-GU Annual Symposium
--
SEATTLE, March 3 /PRNewswire-FirstCall/ -- Dendreon Corporation
(NASDAQ: DNDN) today announced updated results
from its pivotal Phase 3 IMPACT (IMmunotherapy for Prostate
AdenoCarcinoma...



Raptor Pharmaceutical Announces Publication of Data Supporting Potential Efficacy of WntTide(TM) in Treatment of Triple-Negative Breast CancerNOVATO, Calif., Mar 4, 2010 (GlobeNewswire via COMTEX) -- Raptor
Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP)
today announced the publication of data on a proprietary, Mesd
(Mesoderm development)-based peptide, also known as...



Cabazitaxel Increased Survival for Patients with Advanced Hormone-Refractory Prostate Cancer- Results observed in patients treated with cabazitaxel plus
prednisone whose disease progressed despite prior docetaxel-based
chemotherapy - - Data from large international Phase 3 study to be
presented at the 2010 Genitourinary Cancers...



Anavex comments on failure of Pfizer and Medivation's Alzheimer's investigational drug Dimebon during Phase 3 clinical trialsGENEVA, SWITZERLAND, March 3 /PRNewswire-FirstCall/ -- Anavex
Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today issued a
statement following today's announcement from Pfizer and Medivation
(NASDAQ:MDVN) that their investigational
Alzheimer's...



Patient age not a factor in use of second-line therapy for lung cancer'Salvage' therapy just as suitable for NSCLC patients over age
70 as for younger patients
Research published in the March issue of the Journal of Thoracic
Oncology sought to determine whether differences existed in
tolerance and efficacy between...



HIV Vaccine Strategy Expands Immune ResponsesMosaic vaccines show promise in reducing the spread of deadly
virus
LOS ALAMOS, New Mexico, March 3, 2010—Two teams of
researchers—including Los Alamos National Laboratory
theoretical biologists Bette Korber, Will Fischer, Sydeaka...



|
|
|